Cytiva, a global life sciences leader, has partnered with Mycenax Biotech Inc, a leading biopharmaceutical CDMO company, to launch Taiwan’s first continuous bioprocessing lab.
Artiva Biotherapeutics, an oncology company specializing in primary allogeneic natural killer (NK) cell therapies to treat cancer, announced on Aug. 12, 2021 an expansion of its US presence with a new R&D and GMP manufacturing facility in San Diego, Calif., for cell therapies.
New facility at the existing facility in Milford, MA, USA will significantly expand cGMP manufacturing capabilities and accelerate the clinical and commercial supply of vital biopharmaceuticals
Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is opening the Ecolab Healthcare Advanced Design Center in Eagan, Minn.
Precision Cleanrooms’ New Raleigh office will serve customers in North Carolina, South Carolina and the surrounding southeastern United States, providing turnkey cleanroom solutions and services for many industries including: pharmaceutical, biotech, medical device, and microelectronics industries.
As new and novel drug therapies are developed to address areas where conventional medicines are limited, drug delivery innovators, designers and manufacturers have turned to Picocyl for its unique, patented power solutions for drug and implant delivery systems.
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications…
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.
The scientists envision that such transient engineered technologies one day could complement or replace pharmaceutical treatments for a variety of medical conditions in humans. This type of technology, which the researchers refer to as a “bioresorbable electronic medicine,” provides therapy and treatment over a clinically relevant period of time and directly at the site where it’s needed, thereby reducing side effects or risks associated with conventional, permanent implants.
